Equities

Replimune Group Inc

Replimune Group Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)12.44
  • Today's Change0.23 / 1.88%
  • Shares traded291.96k
  • 1 Year change+7.80%
  • Beta1.2234
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in USDView more

In 2024, cash reserves at Replimune Group Inc fell by 72.07m. However, Cash Flow from Investing totalled 97.20m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 185.47m for operations while cash generated from financing totalled 16.28m.
Cash flow per share-3.19
Price/Cash flow per share--
Book value per share6.24
Tangible book value per share6.24
More ▼

Balance sheet in USDView more

Replimune Group Inc has a Debt to Total Capital ratio of 14.31%, a higher figure than the previous year's 10.26%.
Current ratio13.46
Quick ratio--
Total debt/total equity0.1669
Total debt/total capital0.143
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.